The expression of ATF4 is elevated in TMG-treated SY5Y and organoids differentiated from normal individuals, while TMG has no impact on ATF4 expression in organoids derived from AD patients (Alghusen et al., 2023). Here, ATF4 is linked to Alzheimer disease.